Abstract
Cancer cachexia is a highly debilitating paraneoplastic disease observed in more than 50% of patients with advanced cancers and directly contributes to 20% of cancer deaths. Skeletal muscle wasting is a prominent feature of the disease and is believed to result from the loss of balance between protein synthesis and degradation. Quality of life and prognosis are severely compromised in patients with cancer cachexia. Despite current knowledge on the mediators involved in cancer cachexia, treatment targeting a single molecule has rendered limited effectiveness. This article aims to review the mediators of cancer cachexia and interventions attempted in the literature and discuss the common pathways leading to protein loss that these mediators modulate during cachexia. We believe that by targeting downstream effectors that are common in these pathways, a better therapeutic approach to reverse muscle wasting and maintain muscle function during cancer cachexia will be achieved.
Keywords: Cancer cachexia, mediators, metabolism, muscle wasting, signalling, transcription factors, RORα, Calcineurin, RNA-dependent, Protein, myotubes.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Cancer Cachexia: Molecular Targets and Pathways for Diagnosis and Drug Intervention
Volume: 12 Issue: 3
Author(s): Angie M.Y. Shum and Patsie Polly
Affiliation:
Keywords: Cancer cachexia, mediators, metabolism, muscle wasting, signalling, transcription factors, RORα, Calcineurin, RNA-dependent, Protein, myotubes.
Abstract: Cancer cachexia is a highly debilitating paraneoplastic disease observed in more than 50% of patients with advanced cancers and directly contributes to 20% of cancer deaths. Skeletal muscle wasting is a prominent feature of the disease and is believed to result from the loss of balance between protein synthesis and degradation. Quality of life and prognosis are severely compromised in patients with cancer cachexia. Despite current knowledge on the mediators involved in cancer cachexia, treatment targeting a single molecule has rendered limited effectiveness. This article aims to review the mediators of cancer cachexia and interventions attempted in the literature and discuss the common pathways leading to protein loss that these mediators modulate during cachexia. We believe that by targeting downstream effectors that are common in these pathways, a better therapeutic approach to reverse muscle wasting and maintain muscle function during cancer cachexia will be achieved.
Export Options
About this article
Cite this article as:
M.Y. Shum Angie and Polly Patsie, Cancer Cachexia: Molecular Targets and Pathways for Diagnosis and Drug Intervention, Endocrine, Metabolic & Immune Disorders - Drug Targets 2012; 12 (3) . https://dx.doi.org/10.2174/187153012802002910
DOI https://dx.doi.org/10.2174/187153012802002910 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chitosan: A Versatile Biomedical Polymer
Recent Patents on Biomedical Engineering (Discontinued) Mesenchymal Stromal Cells; Role in Tissue Repair, Drug Discovery and Immune Modulation
Current Drug Delivery Lycopene: A Review of Its Potential as an Anticancer Agent
Current Medicinal Chemistry - Anti-Cancer Agents Application of Mitochondria-Targeted Pharmaceuticals for the Treatment of Heart Disease
Current Pharmaceutical Design Genetics and Genomics of Hepatic Acute Phase Reactants: A Mini-Review
Inflammation & Allergy - Drug Targets (Discontinued) The Involvement of Metallothioneins in Mitochondrial Function and Disease
Current Protein & Peptide Science Tyramine Derivatives as Potent Therapeutics for Type 2 Diabetes: Synthesis and <i>In Vitro</i> Inhibition of α-Glucosidase Enzyme
Medicinal Chemistry Neurogenic plasticity of mesenchymal stem cell, an alluring cellular replacement for traumatic brain injury
Current Stem Cell Research & Therapy The Optimal Treatment of Severe Hypertension in Pregnancy: Update of the Role of Nicardipine
Current Pharmaceutical Biotechnology Diet and Metabolic Syndrome: An Overview
Current Vascular Pharmacology Editorial [Hot Topic: Plasminogen Activator Inhibitor-1 (Guest Editor: Daniel A. Lawrence)]
Current Drug Targets Toll Like Receptors in Copd and Periodontal Disease-A Mini Review
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Psychosocial Factors and Diabetes Mellitus: Evidence-Based Treatment Guidelines
Current Diabetes Reviews Therapy Based on the Regulation of Thiol-dependent Redox Systems
Current Medicinal Chemistry Galectin-1 as a Potential Therapeutic Agent for Amyotrophic Lateral Sclerosis
Current Drug Targets An Overview on Diabetic Foot Infections, including Issues Related to Associated Pain, Hyperglycemia and Limb Ischemia
Current Pharmaceutical Design Activities of Quinolones Against Obligately Anaerobic Bacteria
Anti-Infective Agents in Medicinal Chemistry Plant Phenylpropanoids as Emerging Anti-Inflammatory Agents
Mini-Reviews in Medicinal Chemistry TRAIL-Based Therapeutic Approaches for the Treatment of Pediatric Malignancies
Current Medicinal Chemistry Endurance Exercise Training and Reproductive Endocrine Dysfunction in Men Alterations in the Hypothalamic-Pituitary-Testicular Axis
Current Pharmaceutical Design